ATE552270T1 - Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren - Google Patents

Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren

Info

Publication number
ATE552270T1
ATE552270T1 AT00929704T AT00929704T ATE552270T1 AT E552270 T1 ATE552270 T1 AT E552270T1 AT 00929704 T AT00929704 T AT 00929704T AT 00929704 T AT00929704 T AT 00929704T AT E552270 T1 ATE552270 T1 AT E552270T1
Authority
AT
Austria
Prior art keywords
interaction
inducible factor
hypoxia inducible
test methods
tumor suppressor
Prior art date
Application number
AT00929704T
Other languages
English (en)
Inventor
Peter Ratcliffe
Patrick Maxwell
Christopher Pugh
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE552270T1 publication Critical patent/ATE552270T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00929704T 1999-05-12 2000-05-12 Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren ATE552270T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9911047.0A GB9911047D0 (en) 1999-05-12 1999-05-12 Assay method and means
PCT/GB2000/001826 WO2000069908A1 (en) 1999-05-12 2000-05-12 Interaction between the vhl tumour suppressor and hypoxia inducible factor, and assay methods relating thereto

Publications (1)

Publication Number Publication Date
ATE552270T1 true ATE552270T1 (de) 2012-04-15

Family

ID=10853339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929704T ATE552270T1 (de) 1999-05-12 2000-05-12 Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren

Country Status (6)

Country Link
US (3) US6787326B1 (de)
EP (1) EP1179018B1 (de)
JP (3) JP4548944B2 (de)
AT (1) ATE552270T1 (de)
GB (1) GB9911047D0 (de)
WO (1) WO2000069908A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4540294B2 (ja) * 2000-09-27 2010-09-08 東亞合成株式会社 ガン細胞または胚性幹細胞にｖｈｌ遺伝子を導入し、発現して得られる宿主細胞
US7105656B2 (en) 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US7919274B2 (en) * 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
AU2002304163C1 (en) 2001-06-05 2009-01-08 Oriental Yeast Co., Ltd. Polypeptide unstabilizing protein in cells under aerobic conditions and DNA encoding the same
US7358043B2 (en) * 2001-10-16 2008-04-15 Duke University Proteomic interaction and genomic action determinations in the presence of associated redox state conditions
CN102526044A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
AU2003208684A1 (en) * 2002-03-05 2003-09-16 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US8487087B2 (en) * 2005-03-11 2013-07-16 Oriental Yeast Co., Ltd. Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
US7214767B2 (en) 2005-05-25 2007-05-08 Hiroshi Kanno VHL peptide
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
US7728130B2 (en) * 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
CN101420980A (zh) 2006-02-16 2009-04-29 菲布罗根公司 治疗中风的化合物和方法
AU2007334321B2 (en) * 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
EP2111399A2 (de) * 2006-12-18 2009-10-28 Amgen Inc. Naphthalenon-verbindungen mit prolylhydroxylase-hemmungsaktivität sowie zusammensetzungen daraus und anwendungen davon
KR100847694B1 (ko) 2007-02-09 2008-07-23 한국과학기술연구원 프롤린기가 수산화된 ＨＩＦ－１α와 ＶＢＣ 단백질 결합을억제하는 저해제 펩타이드 및 그 제조 방법
CA2683956C (en) * 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2008241577B2 (en) * 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
US8097620B2 (en) * 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
AU2008248234B2 (en) * 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
US20100215697A1 (en) * 2009-02-26 2010-08-26 Stanimir Vuk-Pavlovic Methods and materials for making and using vaccines
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EP2975155A1 (de) * 2014-07-15 2016-01-20 Essilor International (Compagnie Generale D'optique) Verfahren zur physikalischen Dampfabscheidung einer Materialschicht auf Oberflächen von mehreren Substraten
CN107075919A (zh) 2014-11-24 2017-08-18 哈利伯顿能源服务公司 确定钻井工具上的刀具的浸出轮廓
EP3259569B1 (de) * 2015-02-18 2019-08-14 KOC Universitesi Piezoresistiver mehrachsiger kraftsensor
CN110241120A (zh) * 2019-06-28 2019-09-17 西安医学院 转录、转录后和翻译后多水平低氧调控基因、应用及其调控方法
KR102491095B1 (ko) * 2021-01-22 2023-01-20 한국생명공학연구원 Cas 단백질 및 HIF의 TAD 도메인을 포함하는 단백질 융합체 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants

Also Published As

Publication number Publication date
EP1179018B1 (de) 2012-04-04
JP2003500340A (ja) 2003-01-07
JP2009022287A (ja) 2009-02-05
US7709600B2 (en) 2010-05-04
US20100330668A1 (en) 2010-12-30
JP4540728B2 (ja) 2010-09-08
US20050003452A1 (en) 2005-01-06
JP2010246542A (ja) 2010-11-04
JP4548944B2 (ja) 2010-09-22
US6787326B1 (en) 2004-09-07
GB9911047D0 (en) 1999-07-14
WO2000069908A1 (en) 2000-11-23
EP1179018A1 (de) 2002-02-13

Similar Documents

Publication Publication Date Title
ATE552270T1 (de) Wechselwirkung zwischen dem von hippel-lindau tumorsuppressor und hypoxia inducible factor, sowie diesbezügliche testverfahren
WO2019157366A8 (en) Antibody variable domains targeting the nkg2d receptor
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
DE69939864D1 (de) Ppar-gamma modulatoren
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
NO986100D0 (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
MXPA01003344A (es) Composiciones y metodos para inmunoterapia especifica de wt1.
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
CY1108960T1 (el) Αντισωματα αποκλεισμου cripto και οι χρησεις τους
TR199901971T2 (xx) Bir resept�re ba�lanan peptidler ve bile�ikler.
BR0211200A (pt) Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
BR9707819A (pt) Imunogenos peptidicos
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
ATE333465T1 (de) Methoden und mittel zur hemmung der cdk4- aktivität
NO993943D0 (no) Kombinert tumorsuppressorgenterapi og kjemoterapi ved behandling av neoplasmer
MX2023006773A (es) Composiciones de agentes de union a antigenos de guanilato ciclasa c (gcc) y metodos de uso de estos.
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
DE69924738D1 (de) Modulierung von mlk- (multiple lineage kinase) proteinen
AU2002248180A1 (en) Non-apoptotic forms of cell death and methods of modulation
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen